An updated landscape on nanotechnology-based drug delivery, immunotherapy, vaccinations, imaging, and biomarker detections for cancers: recent trends and future directions with clinical success
Source abstract
Abstract
Abstract The recent development of nanotechnology-based formulations improved the diagnostics and therapies for various diseases including cancer where lack of specificity, high cytotoxicity with various side effects, poor biocompatibility, and increasing cases of multi-drug resistance are the major limitations of existing chemotherapy. Nanoparticle-based drug delivery enhances the stability and bioavailability of many drugs, thereby increasing tissue penetration and targeted delivery with improved efficacy against the tumour cells. Easy surface functionalization and encapsulation properties allow various antigens and tumour cell lysates to be delivered in the form of nanovaccines with improved immune response. The nanoparticles (NPs) due to their smaller size and associated optical, physical, and mechanical properties have evolved as biosensors with high sensitivity and specificity for the detection of various markers including nucleic acids, protein/antigens, small metabolites, etc. This review gives, initially, a concise update on drug delivery using different nanoscale platforms like liposomes, dendrimers, polymeric & various metallic NPs, hydrogels, microneedles, nanofibres, nanoemulsions, etc. Drug delivery with recent technologies like quantum dots (QDs), carbon nanotubes (CNTs), protein, and upconverting NPs was updated, thereafter. We also summarized the recent progress in vaccination strategy, immunotherapy involving immune checkpoint inhibitors, and biomarker detection for various cancers based on nanoplatforms. At last, we gave a detailed picture of the current nanomedicines in clinical trials and their possible success along with the existing approved ones. In short, this review provides an updated complete landscape of applications of wide NP-based drug delivery, vaccinations, immunotherapy, biomarker detection & imaging for various cancers with a predicted future of nanomedicines that are in clinical trials. Graphical abstract
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Sutradhar KB, Amin ML. Nanotechnology in cancer drug delivery and selective targeting. Int Sch Res Not. 2014;2014: e939378. https://doi.org/10.1155/2014/939378.10.1155/2014/939378 ↗
2. Tang M-F, Lei L, Guo S-R, Huang W-L. Recent progress in nanotechnology for cancer therapy. Chin J Cancer. 2010;29:775–80. https://doi.org/10.5732/cjc.010.10075.10.5732/cjc.010.10075 ↗
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 201 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492.10.3322/caac.21492 ↗
4. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer.
5. Lancet T. GLOBOCAN 2018: counting the toll of cancer. Lancet. 2018;392(10152):985. https://doi.org/10.1016/S0140-6736(18)32252-9.10.1016/S0140-6736(18)32252-9 ↗
6. Sarkar S, Horn G, Moulton K, Oza A, Byler S, Kokolus S, et al. Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci. 2013;14:21087–113. https://doi.org/10.3390/ijms141021087.10.3390/ijms141021087 ↗
7. Rashid M, Ahmad Z, Tajuddin. Trends in nanotechnology for practical applications. In: Applications of Targeted Nano Drugs and Delivery Systems; 2019. p. 297–325. https://doi.org/10.1016/B978-0-12-814029-1.00011-910.1016/B978-0-12-814029-1.00011-9 ↗
8. Faguet GB. A brief history of cancer: age-old milestones underlying our current knowledge database. Int J Cancer. 2015;136:2022–36. https://doi.org/10.1002/ijc.29134.10.1002/ijc.29134 ↗
9. Hamdy NM, Eskander G, Basalious EB. Insights on the dynamic innovative tumor targeted-nanoparticles-based drug delivery systems activation techniques. Int J Nanomed. 2022;7(17):6131–55. https://doi.org/10.2147/ijn.s386037.10.2147/ijn.s386037 ↗
10. Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol R Coll Radiol G B. 2004;16:549–60. https://doi.org/10.1016/j.clon.2004.06.007.10.1016/j.clon.2004.06.007 ↗
11. IARC Publications Website - World Cancer Report 2014. https://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014.
12. McGuire S. World Cancer Report. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr Bethesda Md. 2014;2016(7):418–9. https://doi.org/10.3945/an.116.012211.10.3945/an.116.012211 ↗
13. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. https://doi.org/10.3322/caac.21442.10.3322/caac.21442 ↗
14. Barnes TA, Amir E, Templeton AJ, Gomez-Garcia S, Navarro B, Seruga B, et al. Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treat Rev. 2017;56:1–7. https://doi.org/10.1016/j.ctrv.2017.03.011.10.1016/j.ctrv.2017.03.011 ↗
15. Li WQ, Guo HF, Li LY, Zhang YF, Cui JW. The promising role of antibody drug conjugate in cancer therapy: combining targeting ability with cytotoxicity effectively. Cancer Med. 2021;10(14):4677–96. https://doi.org/10.1002/cam4.4052.10.1002/cam4.4052 ↗
16. Baron J, Wang ES. Gemtuzumabozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11:549–59. https://doi.org/10.1080/17512433.2018.1478725.10.1080/17512433.2018.1478725 ↗
17. Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biol Targets Ther. 2019;13:33–51. https://doi.org/10.2147/btt.s166310.10.2147/btt.s166310 ↗
18. Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183–97. https://doi.org/10.15252/emmm.201607485.10.15252/emmm.201607485 ↗
19. Farber E. The multistep nature of cancer development. Cancer Res. 1984;44:4217–23.
20. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9:12. https://doi.org/10.3390/pharmaceutics9020012.10.3390/pharmaceutics9020012 ↗
21. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009;69:361–92. https://doi.org/10.2165/00003495-200969030-00010.10.2165/00003495-200969030-00010 ↗
22. Shi L, Wu X, Li T, Wu Y, Song L, Zhang W, et al. An esterase-activatable prodrug formulated liposome strategy: potentiating the anticancer therapeutic efficacy and drug safety. Nanoscale Adv. 2022;4:952–66. https://doi.org/10.1039/D1NA00838B.10.1039/D1NA00838B ↗
23. Singh AK et al. Engineering nanomaterials for smart drug release: recent advances and challenges. In: Applications of targeted nano drugs and delivery systems; 2019. p. 411–449. https://doi.org/10.1016/B978-0-12-814029-1.00015-610.1016/B978-0-12-814029-1.00015-6 ↗
24. Shim G, Lee S, Choi J, Lee S, Kim CW, Oh YK. Liposomal co-delivery of omacetaxine mepesuccinate and doxorubicin for synergistic potentiation of antitumor activity. Pharm Res. 2014;31:2178–85. https://doi.org/10.1007/s11095-014-1317-3.10.1007/s11095-014-1317-3 ↗
25. Chen H, Wan J, Chen D. A novel targeted delivery of valeric acid using liposomal nanoparticles in treatment of lung cell carcinoma. J Biomed Nanotechnol. 2022;18:211–7. https://doi.org/10.1166/jbn.2022.3235.10.1166/jbn.2022.3235 ↗
26. Nakkarach A, Foo HL, Song AA, Mutalib NEA, Nitisinprasert S, Withayagiat U. Anti-cancer and anti-inflammatory effects elicited by short chain fatty acids produced by Escherichia coli isolated from healthy human gut microbiota. Microb Cell Fact. 2021;20(1):36. https://doi.org/10.1186/s12934-020-01477-z.10.1186/s12934-020-01477-z ↗
27. Hodaei M, Varshosaz J. Cationic Okra gum coated nanoliposomes as a pH-sensitive carrier for co-delivery of hesperetin and oxaliplatin in colorectal cancers. Pharm Dev Technol. 2022;27:773–84. https://doi.org/10.1080/10837450.2022.2119249.10.1080/10837450.2022.2119249 ↗
28. Bahutair WN, Abuwatfa WH, Husseini GA. Ultrasound triggering of liposomal nanodrugs for cancer therapy: a review. Nanomaterials (Basel). 2022;12(17):3051. https://doi.org/10.3390/nano12173051.10.3390/nano12173051 ↗
29. Hajinezhad MR, Shahraki S, Nikfarjam Z, Davodabadi F, Mirinejad S, Rahdar A, Sargazi S, Barani M. Development of a new vesicular formulation for delivery of ifosfamide: evidence from in vitro, in vivo, and in silico experiments. Arab J Chem. 2023. https://doi.org/10.1016/j.arabjc.2023.105086.10.1016/j.arabjc.2023.105086 ↗
30. Ashrafizadeh M, Delfi M, Zarrabi A, Bigham A, Sharifi E, Rabiee N, Paiva-Santos AC, Kumar AP, Tan SC, Hushmandi K, Ren J, Zare EN, Makvandi P. Stimuli-responsive liposomal nanoformulations in cancer therapy: pre-clinical & clinical approaches. J Control Release. 2022;351:50–80. https://doi.org/10.1016/j.jconrel.2022.08.001.10.1016/j.jconrel.2022.08.001 ↗
31. Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules. 2022;27(4):1372. https://doi.org/10.3390/molecules27041372.10.3390/molecules27041372 ↗
32. Kumar P, Shivam P, Mandal S, Prasanna P, Kumar S, Prasad SR, Kumar A, Das P, Ali V, Singh SK, Mandal D. Synthesis, characterization, and mechanistic studies of a gold nanoparticle-amphotericin B covalent conjugate with enhanced antileishmanial efficacy and reduced cytotoxicity. Int J Nanomed. 2019;20(14):6073–101. https://doi.org/10.2147/IJN.S196421.10.2147/IJN.S196421 ↗
33. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis. 2004;38(3):377–83. https://doi.org/10.1086/380971.10.1086/380971 ↗
34. Gagliardi A, Giuliano E, Venkateswararao E, Fresta M, Bulotta S, Awasthi V, et al. Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol. 2021;12:601626. https://doi.org/10.3389/fphar.2021.601626.10.3389/fphar.2021.601626 ↗
35. Yang R, Xu J, Xu L, Sun X, Chen Q, Zhao Y, et al. Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination. ACS Nano. 2018;12:5121–9. https://doi.org/10.1021/acsnano.7b09041.10.1021/acsnano.7b09041 ↗
36. Ahmed MM, Fatima F, Anwer MK, Aldawsari MF, Bhatia S, Al-Harrasi A. Brigatinib loaded poly(d, l-lactide-co-glycolide) nanoparticles for improved anti-tumoral activity against non-small cell lung cancer cell lines. Drug Dev Ind Pharm. 2021;47:1112–20. https://doi.org/10.1080/03639045.2021.1983585.10.1080/03639045.2021.1983585 ↗
37. Koerner J, Horvath D, Groettrup M. Harnessing dendritic cells for poly (D, L-lactide-co-glycolide) microspheres (PLGA MS)-mediated anti-tumor therapy. Front Immunol. 2019;10:707. https://doi.org/10.3389/fimmu.2019.00707.10.3389/fimmu.2019.00707 ↗
38. Cruz LJ, Tacken PJ, Fokkink R, et al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release. 2010;144(2):118–26. https://doi.org/10.1016/j.jconrel.2010.02.013.10.1016/j.jconrel.2010.02.013 ↗
39. Mehrotra N, Anees M, Tiwari S, Kharbanda S, Singh H. Polylactic acid based polymeric nanoparticle mediated co-delivery of navitoclax and decitabine for cancer therapy. Nanomed NanotechnolBiol Med. 2023;47: 102627. https://doi.org/10.1016/j.nano.2022.102627.10.1016/j.nano.2022.102627 ↗
40. Fernandes RS, Arribada RG, Silva JO, Silva-Cunha A, Townsend DM, Ferreira LAM, et al. In vitro and in vivo effect of pH-sensitive PLGA-TPGS-based hybrid nanoparticles loaded with doxorubicin for breast cancer therapy. Pharmaceutics. 2022;14:2394. https://doi.org/10.3390/pharmaceutics14112394.10.3390/pharmaceutics14112394 ↗
41. Juan A, Cimas FJ, Bravo I, Pandiella A, Ocaña A, Alonso-Moreno C. An overview of antibody conjugated polymeric nanoparticles for breast cancer therapy. Pharmaceutics. 2020;12:802. https://doi.org/10.3390/pharmaceutics12090802.10.3390/pharmaceutics12090802 ↗
42. Yang X, Iyer AK, Singh A, Milane L, Choy E, Hornicek FJ, et al. Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer. Pharm Res. 2015;32:2097–109. https://doi.org/10.1007/s11095-014-1602-1.10.1007/s11095-014-1602-1 ↗
43. Kim GH, Won JE, Byeon Y, Kim MG, Wi TI, Lee JM, et al. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. Drug Deliv. 2018;25:1394–402. https://doi.org/10.1080/10717544.2018.1480672.10.1080/10717544.2018.1480672 ↗
44. Wang J, Liu D, Guan S, Zhu W, Fan L, Zhang Q, et al. Hyaluronic acid-modified liposomal honokiol nanocarrier: enhance anti-metastasis and antitumor efficacy against breast cancer. CarbohydrPolym. 2020;235:115981. https://doi.org/10.1016/j.carbpol.2020.115981.10.1016/j.carbpol.2020.115981 ↗
45. Thomas AP, Palanikumar L, Jeena MT, Kim K, Ryu J-H. Cancer-mitochondria-targeted photodynamic therapy with supramolecular assembly of HA and a water soluble NIR cyanine dye. Chem Sci. 2017;8:8351–6. https://doi.org/10.1039/c7sc03169f.10.1039/c7sc03169f ↗
46. Yu K, Zhao J, Yu C, Sun F, Liu Y, Zhang Y, et al. Role of four different kinds of polyethylenimines (PEIs) in preparation of polymeric lipid nanoparticles and their anticancer activity study. J Cancer. 2016;7:872–82. https://doi.org/10.7150/jca.13855.10.7150/jca.13855 ↗
47. Zhao M-D, Li J-Q, Chen F-Y, Dong W, Wen L-J, Fei W-D, et al. Co-delivery of curcumin and paclitaxel by core-shell targeting amphiphilic copolymer to reverse resistance in the treatment of ovarian cancer. Int J Nanomedicine. 2019;14:9453–67. https://doi.org/10.2147/IJN.S224579.10.2147/IJN.S224579 ↗
48. Yu K, Zhao J, Zhang Z, Gao Y, Zhou Y, Teng L, et al. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells. Int J Pharm. 2016;497:78–87. https://doi.org/10.1016/j.ijpharm.2015.11.033.10.1016/j.ijpharm.2015.11.033 ↗
49. Sarwar S, Abdul Qadir M, Alharthy RD, et al. Folate conjugated polyethylene glycol probe for tumor-targeted drug delivery of 5-fluorouracil. Molecules. 2022;27(6):1780. https://doi.org/10.3390/molecules27061780.10.3390/molecules27061780 ↗
50. Banerji S, Wright AJ, Noble M, Mahoney DJ, Campbell ID, Day AJ, et al. Structures of the Cd44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction. Nat Struct Mol Biol. 2007;14:234–9. https://doi.org/10.1038/nsmb1201.10.1038/nsmb1201 ↗
51. Liu H, Li K, Lan L, Ma J, Zeng Y, Xu L, et al. Double-layered hyaluronic acid/stearic acid-modified polyethyleneimine nanoparticles encapsulating (-)-gossypol: a nanocarrier for chiral anticancer drugs. J Mater Chem B Mater Biol Med. 2014;2:5238–48. https://doi.org/10.1039/C4TB00539B.10.1039/C4TB00539B ↗
52. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis. 2003;23(Suppl 1):23–8. https://doi.org/10.1055/s-2003-41631.10.1055/s-2003-41631 ↗
53. Mishra P, Nayak B, Dey RK. PEGylation in anti-cancer therapy: an overview. Asian J Pharm Sci. 2016;11:337–48. https://doi.org/10.1016/j.ajps.2015.08.011.10.1016/j.ajps.2015.08.011 ↗
54. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987–92.
55. Zhang J, Chen H, Xu L, Gu Y. The targeted behavior of thermally responsive nanohydrogel evaluated by NIR system in mouse model. J Control Release. 2008;131(1):34–40. https://doi.org/10.1016/j.jconrel.2008.07.019.10.1016/j.jconrel.2008.07.019 ↗
56. Khursheed R, Dua K, Vishwas S, Gulati M, Jha NK, Aldhafeeri GM, et al. Biomedical applications of metallic nanoparticles in cancer: current status and future perspectives. BiomedecinePharmacother. 2022;150:112951. https://doi.org/10.1016/j.biopha.2022.112951.10.1016/j.biopha.2022.112951 ↗
57. Bhattacharyya S, Kudgus RA, Bhattacharya R, Mukherjee P. Inorganic nanoparticles in cancer therapy. Pharm Res. 2011;28:237–59. https://doi.org/10.1007/s11095-010-0318-0.10.1007/s11095-010-0318-0 ↗
58. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res. 2007;24:1029–46. https://doi.org/10.1007/s11095-006-9223-y.10.1007/s11095-006-9223-y ↗
59. Lim Z-ZJ, Li J-EJ, Ng C-T, Yung L-YL, Bay B-H. Gold nanoparticles in cancer therapy. Acta Pharmacol Sin. 2011;32:983–90. https://doi.org/10.1038/aps.2011.82.10.1038/aps.2011.82 ↗
60. Mulens-Arias V, Nicolás-Boluda A, Carn F, Gazeau F. Cationic polyethyleneimine (PEI)-gold nanocomposites modulate macrophage activation and reprogram mouse breast triple-negative MET-1 tumor immunological microenvironment. Pharmaceutics. 2022;14:2234. https://doi.org/10.3390/pharmaceutics14102234.10.3390/pharmaceutics14102234 ↗
61. Giráldez-Pérez RM, Grueso E, Montero-Hidalgo AJ, Luque RM, Carnerero JM, Kuliszewska E, et al. Gold nanosystems covered with doxorubicin/DNA complexes: a therapeutic target for prostate and liver cancer. Int J Mol Sci. 2022;23:15575. https://doi.org/10.3390/ijms232415575.10.3390/ijms232415575 ↗
62. Li C, Zhao L, Jia L, Ouyang Z, Gao Y, Guo R, et al. 68Ga-labeled dendrimer-entrapped gold nanoparticles for PET/CT dual-modality imaging and immunotherapy of tumors. J Mater Chem B. 2022;10:3648–56. https://doi.org/10.1039/d2tb00378c.10.1039/d2tb00378c ↗
63. Sulaiman GM, Waheeb HM, Jabir MS, Khazaal SH, Dewir YH, Naidoo Y. Hesperidin loaded on gold nanoparticles as a drug delivery system for a successful biocompatible, anti-cancer, anti-inflammatory and phagocytosis inducer model. Sci Rep. 2020;10:9362. https://doi.org/10.1038/s41598-020-66419-6.10.1038/s41598-020-66419-6 ↗
64. Kajani AA, Bordbar AK, Esfahanib SHZ, Razmjou A. Gold nanoparticles as potent anticancer agent: green synthesis, characterization, and in vitro study. RSC Adv. 2016;6:63973–83. https://doi.org/10.1039/C6RA09050H10.1039/C6RA09050H ↗
65. Li B, Fu Y, Xie M, Feng L, Niu X, Que L, et al. Gold-based nanoparticles realize photothermal and photodynamic synergistic treatment of liver cancer and improve the anaerobic tumor microenvironment under near-infrared light. Front Bioeng Biotechnol. 2022;10:957349. https://doi.org/10.3389/fbioe.2022.957349.10.3389/fbioe.2022.957349 ↗
66. Liu Y, Crawford BM, Vo-Dinh T. Gold nanoparticles-mediated photothermal therapy and immunotherapy. Immunotherapy. 2018;10:1175–88. https://doi.org/10.2217/imt-2018-0029.10.2217/imt-2018-0029 ↗
67. Han S, Chen C, Chen C, et al. Coupling annealed silver nanoparticles with a porous silicon Bragg mirror SERS substrate and machine learning for rapid non-invasive disease diagnosis. Anal Chim Acta. 2023;1254: 341116. https://doi.org/10.1016/j.aca.2023.341116.10.1016/j.aca.2023.341116 ↗
68. Wu Y, Ali MRK, Dong B, Han T, Chen K, Chen J, et al. Gold nanorod photothermal therapy alters cell junctions and actin network in inhibiting cancer cell collective migration. ACS Nano. 2018;12:9279–90. https://doi.org/10.1021/acsnano.8b04128.10.1021/acsnano.8b04128 ↗
69. Kumari R, Saini AK, Kumar A, Saini RV. Apoptosis induction in lung and prostate cancer cells through silver nanoparticles synthesized from Pinus roxburghii bioactive fraction. J Biol Inorg Chem. 2020;25(1):23–37. https://doi.org/10.1007/s00775-019-01729-3.10.1007/s00775-019-01729-3 ↗
70. Yusuf A, Casey A. Liposomal encapsulation of silver nanoparticles (AgNP) improved nanoparticle uptake and induced redox imbalance to activate caspase-dependent apoptosis. Apoptosis. 2020;25(1–2):120–34. https://doi.org/10.1007/s10495-019-01584-2.10.1007/s10495-019-01584-2 ↗
71. Patil S, Sastry M, Bharde A. Size and shape directed novel green synthesis of plasmonic nanoparticles using bacterial metabolites and their anticancer effects. Front Microbiol. 2022;13:866849. https://doi.org/10.3389/fmicb.2022.866849.10.3389/fmicb.2022.866849 ↗
72. Quan Q, Xie J, Gao H, Yang M, Zhang F, Liu G, et al. HSA coated iron oxide nanoparticles as drug delivery vehicles for cancer therapy. Mol Pharm. 2011;8:1669–76.https://doi.org/10.1021/mp200006f10.1021/mp200006f ↗
73. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103:317–24. https://doi.org/10.1007/s11060-010-0389-0.10.1007/s11060-010-0389-0 ↗
74. Alphandéry E. Bio-synthesized iron oxide nanoparticles for cancer treatment. Int J Pharm. 2020;586:119472. https://doi.org/10.1016/j.ijpharm.2020.119472.10.1016/j.ijpharm.2020.119472 ↗
75. Wang X, Chang Y, Zhang D, Tian B, Yang Y, Wei F. Transferrin-conjugated drug/dye-co-encapsulated magnetic nanocarriers for active-targeting fluorescent/magnetic resonance imaging and anti-tumor effects in human brain tumor cells. RSC Adv. 2016;6:105661–75. https://doi.org/10.1039/C6RA20903C.10.1039/C6RA20903C ↗
76. White EE, Pai A, Weng Y, Suresh AK, Haute DV, Pailevanian T, et al. Functionalized iron oxide nanoparticles for controlling the movement of immune cells. Nanoscale. 2015;7:7780–9. https://doi.org/10.1039/C3NR04421A.10.1039/C3NR04421A ↗
77. Grippin AJ, Wummer B, Wildes T, Dyson K, Trivedi V, Yang C, et al. Dendritic cell-activating magnetic nanoparticles enable early prediction of anti-tumor response with magnetic resonance imaging. ACS Nano. 2019;13:13884–98. https://doi.org/10.1021/acsnano.9b05037.10.1021/acsnano.9b05037 ↗
78. Shevtsov MA, Nikolaev BP, Yakovleva LY, Parr MA, Marchenko YY, Eliseev I, et al. 70-kDa heat shock protein coated magnetic nanocarriers as a nanovaccine for induction of anti-tumor immune response in experimental glioma. J Controlled Release. 2015;220A:329–40. https://doi.org/10.1016/j.jconrel.2015.10.051.10.1016/j.jconrel.2015.10.051 ↗
79. Cho N-H, Cheong T-C, Min JH, Wu JH, Lee SJ, Kim D, et al. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat Nanotechnol. 2011;6:675–82. https://doi.org/10.1038/nnano.2011.149.10.1038/nnano.2011.149 ↗
80. Feng Y, Xie X, Zhang H, Su Q, Yang G, Wei X, et al. Multistage-responsive nanovehicle to improve tumor penetration for dual-modality imaging-guided photodynamic-immunotherapy. Biomaterials. 2021;275:120990. https://doi.org/10.1016/j.biomaterials.2021.120990.10.1016/j.biomaterials.2021.120990 ↗
81. Chiang C-S, Lin Y-J, Lee R, Lai Y-H, Cheng H-W, Hsieh C-H, et al. Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy. Nat Nanotechnol. 2018;13:746–54. https://doi.org/10.1038/s41565-018-0146-7.10.1038/s41565-018-0146-7 ↗
82. Anjum S, Hashim M, Malik SA, Khan M, Lorenzo JM, Abbasi BH, et al. Recent advances in zinc oxide nanoparticles (ZnO NPs) for cancer diagnosis, target drug delivery, and treatment. Cancers. 2021;13:4570. https://doi.org/10.3390/cancers13184570.10.3390/cancers13184570 ↗
83. George D, Maheswari PU, Begum KMMS. Chitosan-cellulose hydrogel conjugated with L-histidine and zinc oxide nanoparticles for sustained drug delivery: kinetics and in-vitro biological studies. Carbohydr Polym. 2020;236:116101. https://doi.org/10.1016/j.carbpol.2020.116101.10.1016/j.carbpol.2020.116101 ↗
84. Hong EJ, Sivakumar P, Ravichandran V, Choi DG, Kim Y-S, Shim MS. Pro-oxidant drug-loaded Au/ZnO hybrid nanoparticles for cancer-specific chemo-photodynamic combination therapy. ACS Biomater Sci Eng. 2019;5:5209–17. https://doi.org/10.1021/acsbiomaterials.9b01339.10.1021/acsbiomaterials.9b01339 ↗
85. AbouAitah K, Soliman AAF, Swiderska-Sroda A, Nassrallah A, Smalc-Koziorowska J, Gierlotka S, et al. Co-delivery system of curcumin and colchicine using functionalized mesoporous silica nanoparticles promotes anticancer and apoptosis effects. Pharmaceutics. 2022;14:2770. https://doi.org/10.3390/pharmaceutics14122770.10.3390/pharmaceutics14122770 ↗
86. Fu J, Mao Y, Han J, Zhang P, Tan Y, Hu J, et al. A nitric oxide and hydrogen sulfide dual-donating nanosystem for highly synergistic gas-radiotherapy against hepatocellular carcinoma. Biomater Adv. 2023;144:213209. https://doi.org/10.1016/j.bioadv.2022.213209.10.1016/j.bioadv.2022.213209 ↗
87. Ruan S, Yin W, Chang J, Yang Y, Sun J, Ma X, et al. Acidic and hypoxic tumor microenvironment regulation by CaO2-loaded polydopamine nanoparticles. J Nanobiotechnol. 2022;20:544. https://doi.org/10.1186/s12951-023-01934-y.10.1186/s12951-023-01934-y ↗
88. Singh D, Yadav E, Falls N, Kumar V, Singh M, Verma A. Phytofabricated silver nanoparticles of Phyllanthus emblica attenuated diethylnitrosamine-induced hepatic cancer via knock-down oxidative stress and inflammation. Inflammopharmacology. 2019;27:1037–54. https://doi.org/10.1007/s10787-018-0525-6.10.1007/s10787-018-0525-6 ↗
89. Soetaert F, Korangath P, Serantes D, Fiering S, Ivkov R. Cancer therapy with iron oxide nanoparticles: agents of thermal and immune therapies. Adv Drug Deliv Rev. 2020;163–164:65–83. https://doi.org/10.1016/j.addr.2020.06.025.10.1016/j.addr.2020.06.025 ↗
90. Geppert M, Himly M. Iron oxide nanoparticles in bioimaging—an immune perspective. Front Immunol. 2021;12:688927. https://doi.org/10.3389/fimmu.2021.688927.10.3389/fimmu.2021.688927 ↗
91. Wiesmann N, Tremel W, Brieger J. Zinc oxide nanoparticles for therapeutic purposes in cancer medicine. J Mater Chem B. 2020;8:4973–89. https://doi.org/10.1039/D0TB00739K.10.1039/D0TB00739K ↗
92. Rani S, Kumar P, Dahiya P, Dang AS, Suneja P. Biogenic synthesis of zinc nanoparticles, their applications, and toxicity prospects. Front Microbiol. 2022. https://doi.org/10.3389/fmicb.2022.824427.10.3389/fmicb.2022.824427 ↗
93. Stepankova H, Swiatkowski M, Kruszynski R, Svec P, Michalkova H, Smolikova V, et al. The anti-proliferative activity of coordination compound-based ZnO nanoparticles as a promising agent against triple negative breast cancer cells. Int J Nanomedicine. 2021;16:4431–49. https://doi.org/10.2147/IJN.S304902.10.2147/IJN.S304902 ↗
94. Castro RI, Forero-Doria O, Guzmán L. Perspectives of dendrimer-based nanoparticles in cancer therapy. An Acad Bras Cienc. 2018;90(2 suppl 1):2331–46. https://doi.org/10.1590/0001-3765201820170387.10.1590/0001-3765201820170387 ↗
95. Zaimy MA, Saffarzadeh N, Mohammadi A, Pourghadamyari H, Izadi P, Sarli A, et al. New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther. 2017;24:233–43. https://doi.org/10.1038/cgt.2017.16.10.1038/cgt.2017.16 ↗
96. Singh V, Kesharwani P. Dendrimer as a promising nanocarrier for the delivery of doxorubicin as an anticancer therapeutics. J Biomater Sci Polym Ed. 2021;32:1882–909. https://doi.org/10.1080/09205063.2021.1938859.10.1080/09205063.2021.1938859 ↗
97. Zhao W, Yang S, Li C, Li F, Pang H, Xu G, et al. Amphiphilic dendritic nanomicelle-mediated delivery of gemcitabine for enhancing the specificity and effectiveness. Int J Nanomed. 2022;17:3239–49. https://doi.org/10.2147/ijn.s371775.10.2147/ijn.s371775 ↗
98. Öztürk K, Esendağlı G, Gürbüz MU, Tülü M, Çalış S. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers. Int J Pharm. 2017;517:157–67. https://doi.org/10.1016/j.ijpharm.2016.12.009.10.1016/j.ijpharm.2016.12.009 ↗
99. Dong Y, Yu T, Ding L, Laurini E, Huang Y, Zhang M, et al. A dual targeting dendrimer-mediated siRNA delivery system for effective gene silencing in cancer therapy. J Am Chem Soc. 2018;140:16264–74. https://doi.org/10.1021/jacs.8b10021.10.1021/jacs.8b10021 ↗
100. Mignani S, Rodrigues J, Tomas H, Zablocka M, Shi X, Caminade A-M, et al. Dendrimers in combination with natural products and analogues as anti-cancer agents. Chem Soc Rev. 2018;47:514–32. https://doi.org/10.1039/C7CS00550D.10.1039/C7CS00550D ↗